Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer

SIMPLE SUMMARY: HER2-low breast cancer is a new entity featuring low HER2 expression (HER2 1+ or HER2 2+/FISH−) and can potentially benefit from novel antibody-drug conjugates. A precise estimation of HER2-low expression is warranted. Here, we found that HER2 1+ and HER2 0 tumors shared similar clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Lan, Tong, Yiwei, Li, Zhuoxuan, Chen, Xiaosong, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455006/
https://www.ncbi.nlm.nih.gov/pubmed/36077795
http://dx.doi.org/10.3390/cancers14174250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455006/
https://www.ncbi.nlm.nih.gov/pubmed/36077795
http://dx.doi.org/10.3390/cancers14174250

Ejemplares similares